GlassScriptPhysician profile
Arun Nangia
NPI 1194794099
$4,346.55
in general payments reported to CMS, 2019-2025
51 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $351 · 2021: $506 · 2022: $502 · 2023: $769 · 2024: $841 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,271.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $767.44 | 2021-2025 | |
| Lilly USA, LLC | $432.22 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Teva Pharmaceuticals USA, INC. | $337.48 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Ucb, INC. | $304.73 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Sk Life Science, INC. | $289.76 | 2021-2025 | |
| Allergan, INC. | $209.27 | 2019-2020 | |
| Mdd US Operations, LLC | $205.54 | 2019-2025 | Apokyn |
| Amgen INC. | $175.37 | 2019-2023 | Aimovig |
| Pfizer INC. | $160.38 | 2023-2025 | |
| Lundbeck LLC | $142.42 | 2019-2025 | Vyepti |
| Emd Serono, INC. | $124.98 | 2022 | |
| Novartis Pharmaceuticals Corporation | $115.64 | 2019 | |
| Neurelis, INC. | $96.89 | 2021-2025 | Valtoco |
| Biogen, INC. | $67.58 | 2019 | |
| Amneal Pharmaceuticals LLC | $46.00 | 2019-2025 | Brekiya |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Nangia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.